novartis glp-1 receptor agonist weight management diabetes treatments Agonists as for Type 2 Pfizer Phase IIb Data Support
Description
no major safety concerns were observed
The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence
Read Important Safety and Prescribing Information, including Boxed Warning.
The glp-1 agonists market is expected to reach US$ 118,926.1 billion by 2032, growing at a significant CAGR of 18.1% from 2026 to 2032.
